Valeant Left Out, Actavis Acquires Allergan in $66B Deal

The transcript discusses Valiant's offer and its implications for shareholders, noting that the acquirer's stock is up, indicating investor approval. It explores potential future mergers in the pharmaceutical space, particularly inversion deals, and highlights trends in biotech and pharma investments. The discussion also predicts growth in the animal health market, emphasizing its global significance beyond pets.

What was the initial share price discussed for Valiant before considering a higher offer?

• $180

• $200

• $219

• $205

How did the market react to the acquirer's stock after the deal announcement?

• It decreased by 2/10 of 1%

• It increased by 3.4%

• It remained flat

• It decreased by 3.4%

What is a significant factor that influences the success of a merger deal according to the transcript?

• Competitor actions

• Shareholder sentiment

• Government regulations

• Market size

What type of deals are expected to increase in the pharmaceutical industry?

• Real estate investments

• Technology acquisitions

• Retail mergers

• Inversion deals

Which market is predicted to see a lot of deals in 2015 according to the transcript?

• Biotechnology

• Human pharmaceuticals

• Animal health

• Pet care